who we are
Pfizer Finland is a subsidiary of Pfizer Inc., one of the world´s leading bio pharmaceutical companies. Pfizer’s revenues in 2016 were 53 billion dollars. With 63 manufacturing sites worldwide, we sell products in 175 markets and employ over 97,000 people. Our CEO is Ian Read.
Our purpose is to innovate to bring therapies to patients that significantly improve their lives. Our mission is to be the premier, innovative pharmaceutical company.
Pfizer has a leading portfolio of products and medicines that support wellness and prevention, as well as treatment and cures for diseases across a broad range of therapeutic areas. We also have an industry-leading pipeline of promising new products that have the potential to challenge some of the most feared diseases of our time, including Alzheimer's disease and cancer.
Founded in 1959, Pfizer Finland is one of the largest pharmaceutical companies operating in Finland today with revenue of 145 million euro (2016). Headquartered in Helsinki, Pfizer Finland employs around 130 people. Our CEO is Päivi Kerkola. Pfizer Finland is part of Pfizer’s global commercial organization structure with these business units:
- Pfizer Innovative Health: Inflammation & Immunology, Internal Medicine, Rare Disease, Oncology, Vaccines, Consumer Healthcare
- Pfizer Essential Health: Anti-Infectives, Women's Health, Biosimilars, Off-Patent Products
what we do
Research and development is at the heart Pfizer’s purpose. Since Pfizer was founded in 1849, we have remained dedicated to discovering and developing new, and better, ways to prevent and treat disease and improve health and well-being for people around the world. Annually, Pfizer spends 7-8 billion dollars on research and development, focusing our resources on disease areas with the best chance of scientific and commercial success. Our focus areas are:
• Cardiovascular & Metabolic Disease
• Inflammation & Immunology
• Neuroscience & Pain
• Rare Disease
Pfizer has active R&D efforts in Finland with several ongoing clinical trials involving approximately 1,300 Finns. Pfizer is also active in Finnish society. We collaborate with various stakeholders and discuss with the authorities and decision-makers regarding the Finnish healthcare system and Pfizer´s R&D opportunities in Finland. Pfizer has also contributed to the National Research and Innovation Growth Strategy whose aim is to attract more health investments and generate economic growth in Finland. We are focused on improving the way we do business. We operate with transparency in everything we do and listen to the views of all of the parties involved in healthcare decisions.
Business Unit Leaders and contact information (in Finnish): http://www.pfizer.fi/yhteystiedot
For our newest press releases (in Finnish): http://www.pfizer.fi/medialle#